Allogene Therapeutics, Inc.

5.15 USD
+0.01 (+0.10%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Allogene Therapeutics, Inc. stock is up 45.34% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 February’s closed higher than January. In the last 2 Unusual Options Trades, there were 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 Jan 20:46 17 May, 2024 2.50 CALL 997 146
20 Feb 20:56 16 Aug, 2024 5.00 CALL 802 1050

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.